Baxter announces CEO’s immediate retirement, days after $3.7B sale of kidney care business
Deerfield-based Baxter International announced Monday that its CEO and board Chair José Almeida is retiring, effective ...
Baxter International: A Possible Value Trap
Despite strong revenue growth, Baxter struggles with profitability and high long-term debt. Click here to read why BAX stock ...
Baxter International Inc. CEO Transition and Financial Update
Baxter International Inc. (NYSE: BAX) has recently announced significant changes to its executive leadership and provided an update on its financial outlook through an 8-K filing with the Securities ...
Baxter International Weighing Potential Tariff Impact
Baxter International said it weighing the potential impact of the Trump administration's planned tariffs on the medical-products maker's guidance.
Baxter Kidney Care is Now Vantive, A New Standalone Vital Organ Therapy Company
Vantive builds on a 70-year legacy of kidney care leadership and innovation, with a singular focus on empowering patients and ...
Baxter Kidney Care becomes Vantive following acquisition by Carlyle funds
Vantive, formerly the Baxter Kidney Care segment, launched as a new standalone vital organ therapy company following the completion of its ...
Barchart on MSN1d
Baxter International Stock: Is Wall Street Bullish or Bearish?
Deerfield, Illinois-based Baxter International Inc. (BAX) functions as a healthcare company providing medical products and ...
Baxter International: An Uncompelling Investment With High Debt
I critique Baxter International's capital allocation decisions, stating the stock is not suitable for popular investment strategies. See why I rate BAX a sell.